SBL
ATRS

Sargent Bickham Lagudis’s Antares Pharma, Inc. ATRS Stock Holding History

Sargent Bickham Lagudis’s Portfolio ATRS Stock Details ATRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-450
Closed -$2K – 1046
2021
Q3 		$2K Hold
450
– – ﹤0.01% 899
2021
Q2 		$2K Buy
+450
New +$1.83K ﹤0.01% 880

Other funds holding ATRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Amundi
Amundi Paris, France $367B AUM 31.23% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

Sargent Bickham Lagudis's ATRS Position: Q4 2021 in Review

Sargent Bickham Lagudis sold out of Antares Pharma, Inc. (ATRS) in Q4 2021, closing a stake of 450 shares — an estimated $2K sold.

Sargent Bickham Lagudis first reported a position in ATRS in Q2 2021 and held it in 2 quarters. The position peaked at $2K in Q3 2021. 162 funds tracked by Wall St. Rank hold ATRS as of Q4 2021.

  • Sargent Bickham Lagudis reported no remaining Antares Pharma, Inc. position as of Q4 2021 after selling out during the quarter.
  • Sargent Bickham Lagudis sold 450 Antares Pharma, Inc. shares in Q4 2021, an estimated $2K.
  • Sargent Bickham Lagudis first reported a position in Antares Pharma, Inc. in Q2 2021 and held it in 2 quarters.
  • Sargent Bickham Lagudis's Antares Pharma, Inc. position peaked at $2K in Q3 2021.
  • 162 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q4 2021.

Based on Sargent Bickham Lagudis's 13F filing for Q4 2021, filed 18 Jan 2022.